未登录 Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2 Buparlisib联合氟维司坦与安慰剂联合氟维司坦治疗绝经后，激素受体阳性，人表皮生长因子受体2阴性的晚期乳腺癌: BELLE-2的总生存期结果 Campone, Mario; Im, Seock-Ah; Iwata, Hiroji; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiello-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Cortes, Javier; De Laurentiis, Michele; Arteaga, Carlos L.; Jiang, Zefei; Jonat, Walter; Le Mouhaer, Sylvie; Sankaran, Banu; Bourdeau, Laurence; El-Hashimy, Mona; Sellami, Dalila; Baselga, Jose 分享 收藏
分享 收藏
PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial Baselga, J.; Im, S-A; Iwata, H.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiello-Gruszfeld, A.; Pistilli, B.; Tseng, L-M; Hurvitz, S.; Masuda, N.; Cortes, J.; De Laurentiis, M.; Arteaga, C. L.; Jiang, Z.; Jonat, W.; Hachemi, S.; Le Mouhaer, S.; Di Tomaso, E.; Urban, P.; Massacesi, C.; Campone, M. 分享 收藏
Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial O'Shaughnessy, J.; Yardley, D. A.; Burris, H. A.; De Boer, R.; Amadori, D.; McIntyre, K.; Ejlertsen, B.; Gnant, M.; Jonat, W.; Pritchard, K. I.; Dowsett, M.; Hart, L.; Poggio, S.; Valagussa, P.; Salomon, H.; Wamil, B.; Smith, I. 分享 收藏
分享 收藏
Inhibition of osteolytic tumor growth by 5-FdU-alendronate, a bisphosphonate conjugate that maintains bone formation: Implications for treatment of osteolytic bone lesions Schem, Christian; Tower, Rob J.; Kneissl, Philipp; Rambow, Anna C.; Campbell, Graeme M.; Heilmann, Thorsten; Trauzold, Anna; Jonat, Walter; Glueer, Claus C.; Schott, Sarah; Tiwari, Sanjay 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases Schem, Christian; Bauerschlag, Dirk; Bender, Sascha; Lorenzen, Ann-Christin; Loermann, Daniel; Hamann, Sigrid; Roesel, Frank; Kalthoff, Holger; Glueer, Claus C.; Jonat, Walter; Tiwari, Sanjay 分享 收藏
分享 收藏
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals 乳腺成纤维细胞通过机械和旁分泌信号调节正常和致瘤性乳腺上皮细胞的形态发生 Luehr, Inke; Friedl, Andreas; Overath, Thorsten; Tholey, Andreas; Kunze, Thomas; Hilpert, Felix; Sebens, Susanne; Arnold, Norbert; Roesel, Frank; Oberg, Hans-Heinrich; Maass, Nicolai; Mundhenke, Christoph; Jonat, Walter; Bauer, Maret 分享 收藏
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer 评估阿法替尼在广泛预处理的HER2-negative转移性乳腺癌患者中的疗效和安全性的II期试验 Schuler, Martin; Awada, Ahmad; Harter, Philipp; Canon, Jean Luc; Possinger, Kurt; Schmidt, Marcus; De Greve, Jacques; Neven, Patrick; Dirix, Luc; Jonat, Walter; Beckmann, Matthias W.; Schuette, Jochen; Fasching, Peter A.; Gottschalk, Nina; Besse-Hammer, Tatiana; Fleischer, Frank; Wind, Sven; Uttenreuther-Fischer, Martina; Piccart, Martine; Harbeck, Nadia 分享 收藏
The sequential use of endocrine treatment for advanced breast cancer: where are we? Barrios, C.; Forbes, J. F.; Jonat, W.; Conte, P.; Gradishar, W.; Buzdar, A.; Gelmon, K.; Gnant, M.; Bonneterre, J.; Toi, M.; Hudis, C.; Robertson, J. F. R. 分享 收藏
Interventional bleeding, hematoma and scar-formation after vacuum-biopsy under stereotactic guidance: Mammotome®-system 11g/8g vs. ATEC®-system 12g/9g Schaefer, F. K. W.; Order, B. M.; Eckmann-Scholz, C.; Strauss, A.; Hilpert, F.; Kroj, K.; Biernath-Wuepping, J.; Heller, M.; Jonat, W.; Schaefer, P. J. 分享 收藏
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management 德国乳腺癌患者BRCA1和BRCA2突变的双重杂合性: 对测试策略和临床管理的影响 Heidemann, Simone; Fischer, Christine; Engel, Christoph; Fischer, Barbara; Harder, Lana; Schlegelberger, Brigitte; Niederacher, Dieter; Goecke, Timm O.; Doelken, Sandra C.; Dikow, Nicola; Jonat, Walter; Morlot, Susanne; Schmutzler, Rita C.; Arnold, Norbert K. 分享 收藏
Imatinib Mesylate in Combination with Vinorelbine for Patients with Metastatic Breast Cancer An Ongoing Phase I/II Clinical Trial. Mundhenke, C.; Schem, C.; Bauerschlag, D. O.; Weigel, M. T.; Hilpert, F.; Eidtmann, H.; Tiemann, K.; Muth, M.; May, C.; Hanson, S.; Jonat, W.; Maass, N. 分享 收藏
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer Stemmler, H. J.; diGioia, D.; Freier, W.; Tessen, H. W.; Gitsch, G.; Jonat, W.; Brugger, W.; Kettner, E.; Abenhardt, W.; Tesch, H.; Hurtz, H. J.; Roesel, S.; Brudler, O.; Heinemann, V. 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
